Efficacy of ITI 007 Related with Mood Regulation and Mental Disorder

Schizophrenia imposes a heavy burden on both the individual and society. A wide range of symptoms, including as psychosis, hallucinations, delusions, and associated positive feelings, as well as difficulties in social functioning, cognitive problems, and, frequently, debilitating mood disorders like chronic depression, are used to describe the disease. Often, lifelong medication is necessary for the diseases management. A novel antipsychotic drug called lumateperone ITI 007, CAPLYTATM was discovered and created by Intra Cellular Therapies, Inc. ITCI and was authorized for the treatment of schizophrenia in adults in December 2019. Serotonin, dopamine, and glutamate neurotransmission, three important neurotransmitters linked to schizophrenia, are simultaneously modulated by lumateperone. The US Food and Drug Administration has authorized its use. Patients with treatment resistant schizophrenia and those who are at risk of developing metabolic dysfunction should take into account using lumateperone abnormalities of movement. Lumateperone should not be used, however, in the following situations a women who are pregnant or nursing b children, adolescents, and elderly patients with dementia related psychosis c patients who are at risk for cerebrovascular diseases d patients who use alcohol or other sedative drugs and e patients who use inducers and moderate or strong inhibitors of the cytochrome P450 3A4 CYP3A4 isozyme. Future research will lay the groundwork for identifying the proof for thorough analyses of the function of lumateperone in the treatment of those with schizophrenia and other illnesses. Ms. Bhusare Kalpana Marutirao | Mr. Salvi Ajay Sanjay "Efficacy of ITI-007 Related with Mood Regulation and Mental Disorder" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-7 | Issue-4, August 2023, URL: https://www.ijtsrd.com/papers/ijtsrd59645.pdf Paper Url:https://www.ijtsrd.com/pharmacy/other/59645/efficacy-of-iti007-related-with-mood-regulation-and-mental-disorder/ms-bhusare-kalpana-marutirao